Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00976911
First received: September 14, 2009
Last updated: September 22, 2014
Last verified: September 2014
  Purpose

This randomized, open-label, 2-arm study will evaluate the efficacy and safety o f Avastin added to chemotherapy versus chemotherapy alone in patients with epith elial ovarian, fallopian tube or primary peritoneal cancer with disease progress ion within 6 months of platinum therapy. All patients will receive standard chem otherapy with either paclitaxel or topotecan or liposomal doxorubicin. Patients randomized to Arm 2 of the study will receive Avastin (10mg/kg iv 2-weekly or 15 mg/kg iv 3-weekly) concomitantly. Anticipated time on study treatment is until d isease progression. Patients will then receive standard of care, those in Arm 1 (chemotherapy only) may opt to receive Avastin (15mg/kg iv 3-weekly). Target sam ple size is 100-500 individuals.


Condition Intervention Phase
Ovarian Cancer
Drug: bevacizumab [Avastin]
Drug: liposomal doxorubicin
Drug: paclitaxel
Drug: topotecan
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: AURELIA: A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: tumour assessments every 8-9 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Objective response rate, biological progression-free interval, overall survival [ Time Frame: tumour assessments every 8-9 weeks ] [ Designated as safety issue: No ]
  • Quality of life: EORTC, HADS, FOSI [ Time Frame: weeks 8, 16 and 24 or 9, 18 and 27 ] [ Designated as safety issue: No ]
  • Safety and tolerability: AEs, laboratory parameters, ECOG performance status, vital signs [ Time Frame: throughout study, laboratory and ECOG assessments every 2-3 weeks ] [ Designated as safety issue: No ]

Enrollment: 361
Study Start Date: October 2009
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: liposomal doxorubicin
40mg/m2 iv every 4 weeks
Drug: paclitaxel
80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
Drug: topotecan
4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
Experimental: 2 Drug: bevacizumab [Avastin]
10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
Drug: liposomal doxorubicin
40mg/m2 iv every 4 weeks
Drug: paclitaxel
80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
Drug: topotecan
4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • female patients, >/=18 years of age
  • epithelial ovarian, fallopian tube or primary peritoneal cancer
  • platinum-resistant disease (disease progression within <6 months of platinum therapy)
  • EOCG performance status of 0-2

Exclusion Criteria:

  • non-epithelial tumours
  • ovarian tumours with low malignant potential
  • previous treatment with >2 chemotherapy regimens
  • prior radiotherapy to the pelvis or abdomen
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00976911

  Show 121 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided by Hoffmann-La Roche

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00976911     History of Changes
Other Study ID Numbers: MO22224, 2009-011400-33
Study First Received: September 14, 2009
Last Updated: September 22, 2014
Health Authority: Spain: Ministry of Health

Additional relevant MeSH terms:
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Bevacizumab
Doxorubicin
Liposomal doxorubicin
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on November 25, 2014